Orexo

Report Publication Announcement • Jan 15, 2008

Press release January 15, 2008

Orexo AB – Financial calendar 2008

Orexo AB (publ) today announced the following preliminary dates for the release of its quarterly reports and the Annual General Meeting in 2008:

Q4 2007, Full Year Report 2007 – February 15, 2008 Q1 2008, Interim Report January – March 2008 – May 7, 2008 Q2 2008, Interim Report January – June 2008 – August 14, 2008 Q3 2008, Interim Report January – September 2008 – November 10, 2008

Annual General Meeting (Stockholm) – April 3 at 17.00.

For more information, please contact

Claes Wenthzel, Executive Vice President and CFO, Orexo AB +46 (0)18 780 88 44, e-mail: claes.wenthzel@orexo.com

TO THE EDITORS

About Orexo

Orexo is a specialty pharmaceutical company, focusing on development of new, patented drugs by combining welldocumented substances with innovative technologies, and the development of new treatments for respiratory and inflammatory diseases.

Orexo has a broad and competitive late-stage product portfolio, including two marketed products, five products in clinical phase and two undergoing registration.

To date, Orexo have out-licensed the market rights for Rapinyl for the US, the EU and Japan markets, and signed a research collaboration with Boehringer Ingelheim regarding the development of a new class of drugs to treat pain and inflammation. Also, Orexo has established a Nordic sales force by entering into a joint venture with ProStrakan.

Orexo has head office in Uppsala and is listed on the OMX Nordic Exchange Stockholm, Small Cap (ticker: ORX).

www.orexo.com